Cambridge, Mass - April 22, 2014 - Genzyme, ett bolag i Sanofi-koncernen (EURONEXT: SAN och NYSE: SNY), meddelade idag att 18 poster- och muntliga presentationer om Aubagio (teriflunomide) och Lemtrada (alemtuzumab) för behandling av MS (multipel skleros) kommer att presenteras under den 66: e American Academy of Neurology (AAN) kongressen som hålls i Philadelphia, 26 april-3 maj 2014.
NLT-gruppen rekommenderar landstingen att använda Lemtrada (alemtuzumab) för behandling av aktiv skovvis förlöpande MS. Lemtrada blev godkänt för användning inom EU i september 2013 och är det första utvalda läkemedel som ingår i ett pilotprojekt med en ny gemensam process för ordnat införande.
Cambridge, Massachusetts – 17 september 2013 – Genzyme, ett bolag i Sanofikoncernen (EURONEXT: SAN och NYSE: SNY) meddelade idag att den Europeiska kommissionen har gett marknadsföringstillstånd för Lemtrada™. Detta kommer kort tid efter godkännandet för Aubagio® som tillkännagavs den 30:e augusti. Företaget har som målsättning att snart börja lansera båda produkterna inom EU.
Cambridge, Massachusetts USA. – 2 september 2013 – Genzyme, ett bolag ägt av Sanofi (EURONEXT: SAN och NYSE: SNY), meddelade idag att den Europeiska kommissionen har godkänt Aubagio® (teriflunomid) 14 mg, ett oralt läkemedel som ska tas en gång om dagen, för behandling av skovvis förlöpande multipel skleros (RRMS, relapsing-remitting MS).
Cambridge, Mass. – June 28, 2013 – Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for approval of LEMTRADA™ (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.
Paris, France - June 24, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) and GDF SUEZ, through its subsidiary Cofely (GDF Suez Energie Services), today announced the signing of an agreement to strengthen their collaboration by implementing projects in the field of energy at Sanofi industrial sites. The five-year contract includes mainly renewable energy production and distribution systems.
EURONEXT: SAN and NYSE: SNY announced today that the first phase 3 study results for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus® (insulin glargine [rDNA origin] injection). The company also announced topline results of a second Phase 3 study (EDITION II) for new insulin.
Sanofi (EURONEXT: SAN and NYSE: SNY) and the Curie Institute, through its Curie-Cancer partnership under the Institut Carnot label, announce today the establishment of a three-year research collaboration to identify new therapeutic targets for the development of treatments for ovarian cancer.
Sanofi announced today that clinical data highlighting the company’s ongoing commitment to advancing diabetes care will be presented at the American Diabetes Association (ADA) 73rd Scientific Sessions in Chicago, USA. In total, more than 60 abstracts representing new data sets on Sanofi diabetes drugs, investigational drugs or medical devices are part of the official scientific program.
Sanofi (EURONEXT: SAN and NYSE: SNY) announced today thatthe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency(EMA) has issued a positive opinion for inclusion in the Lantus® (insulin glargine) product label of safety and efficacy data from the insulin glargine cardiovascular (CV) outcomes trial ORIGIN(Outcome Reduction with Initial Glargine INtervention).
Paris, France - May 23, 2013 - Sanofi (EURONEXT : SAN and NYSE : SNY) is pleased to announce today the appointment of David Loew, as Senior Vice President, Commercial Operations, Europe, effective July 1st , 2013. He will report to Peter Guenter in his new role as Executive Vice President, David will join the Global Leadership Team and become Chairman of the European Strategic Committee.
Pollensäsongen blir längre och längre samtidigt som antalet pollenallergiker växer stadigt. Bara i Sverige lider uppskattningsvis 1 150 000 personer av pollenallergi. Trots detta finns det idag ett stort kunskapsglapp kring pollenallergi.
Sanofi and its subsidiary Genzyme announced today positive top-line results from the TOPIC trial for AUBAGIO (teriflunomide). The trial was designed to assess whether early initiation of AUBAGIO (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome can prevent or delay conversion to clinically definite multiple sclerosis (CDMS).
Paris, France, and South San Francisco, California - April 11, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) and PATH’s Drug Development program, established through an affiliation with OneWorld Health, today announced the launch of the large-scale production line of semisynthetic artemisinin at Sanofi’s Garessio site in Italy.
Sanofi meddelar idag att de erhållit ett europeiskt godkännande av aflibercept 25 mg/ml för behandling av metastaserad kolorektal cancer. Aflibercept, som i Sverige kommer att marknadsföras under namnet ZALTRAP, ges som andra linjens behandling i kombination med FOLFIRI. Kombinationen har i studier visat signifikant förlängd total överlevnad hos patienter med metastaserad kolorektalcancer.
Sanofi lanserar ny behandling: den första prandiella GLP-1 receptoragonisten, som tas en gång per dag i samband med måltid
Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that Hanspeter Spek, President, Global Operations, will retire from his current role in mid-2013. A succession plan will be announced in due course.
Sanofi announced today that new research spanning the company’s marketed and investigational hematology products, including its late-stage selective JAK2 inhibitor, will be featured in 178 abstracts to be presented at the 2012 Annual Meeting of the American Society of Hematology in Atlanta, GA., December 8-11, 2012.
Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it ranked third among twenty pharmaceutical companies on the 2012 Access to Medicine Index (ATM Index) created by the Access to Medicine Foundation, an international non-profit organization dedicated to improving access to medicine to societies in need.
Sanofi meddelade idag att kommittén för humanläkemedel (CHMP) vid Europeiska läkemedelsmyndigheten (EMA) har utfärdat ett positivt yttrande där man rekommenderar godkännande av Lyxumia ® (lixisenatid) en gång dagligen för behandling av vuxna med typ 2-diabetes för att uppnå glykemisk kontroll i kombination med orala glukossänkande läkemedel och/eller basinsulin.